Xiaobin Wu Sells 39,936 Shares of BeOne Medicines (NASDAQ:ONC) Stock

Key Points

• Xiaobin Wu, COO of BeOne Medicines Ltd., sold a total of 39,936 shares on August 14th for over $12 million, following a similar transaction just a day earlier involving 49,858 shares.
• BeOne Medicines recently reported an EPS of $0.84 for the last quarter, exceeding expectations of $0.48, and had revenue of $1.32 billion.
• The stock price of BeOne Medicines fluctuated, reaching $321.36 recently, with analysts recently upgrading their price targets to between $330.00 and $365.00 per share.

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) COO Xiaobin Wu sold 39,936 shares of the stock in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $305.06, for a total value of $12,182,876.16. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Xiaobin Wu also recently made the following trade(s):

• On Wednesday, August 13th, Xiaobin Wu sold 49,858 shares of BeOne Medicines stock. The shares were sold at an average price of $304.16, for a total value of $15,164,809.28.
• On Monday, June 23rd, Xiaobin Wu sold 1,363 shares of BeOne Medicines stock. The stock was sold at an average price of $260.00, for a total value of $354,380.00.
• On Tuesday, June 17th, Xiaobin Wu sold 630 shares of BeOne Medicines stock. The stock was sold at an average price of $250.87, for a total transaction of $158,048.10.
• On Monday, June 16th, Xiaobin Wu sold 1,543 shares of BeOne Medicines stock. The shares were sold at an average price of $265.52, for a total transaction of $409,697.36.
• On Friday, June 6th, Xiaobin Wu sold 1,934 shares of BeOne Medicines stock. The stock was sold at an average price of $253.15, for a total transaction of $489,592.10.

BeOne Medicines Stock Performance

Shares of BeOne Medicines stock traded down $3.18 during trading hours on Wednesday, reaching $309.33. The company's stock had a trading volume of 248,257 shares, compared to its average volume of 424,248. BeOne Medicines Ltd. - Sponsored ADR has a one year low of $170.99 and a one year high of $330.63. The business's 50 day moving average price is $277.65. The company has a current ratio of 1.95, a quick ratio of 1.72 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $33.90 billion, a PE ratio of -178.80 and a beta of 0.27.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $0.84 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.36. BeOne Medicines had a negative net margin of 3.89% and a negative return on equity of 1.22%. The business had revenue of $1.32 billion during the quarter, compared to the consensus estimate of $1.24 billion. On average, sell-side analysts predict that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current fiscal year.

Analyst Ratings Changes

ONC has been the topic of several recent research reports. Morgan Stanley raised their price target on BeOne Medicines from $313.00 to $330.00 and gave the stock an "overweight" rating in a report on Friday, June 27th. TD Securities reiterated a "buy" rating and issued a $334.00 target price on shares of BeOne Medicines in a research note on Thursday, April 24th. Wall Street Zen raised shares of BeOne Medicines from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 9th. JPMorgan Chase & Co. increased their price objective on shares of BeOne Medicines from $321.00 to $345.00 and gave the stock an "overweight" rating in a report on Thursday, July 17th. Finally, Guggenheim lifted their price objective on shares of BeOne Medicines from $350.00 to $365.00 and gave the company a "buy" rating in a research report on Thursday, August 7th. Seven equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $330.89.

Institutional Investors Weigh In On BeOne Medicines

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Anchor Investment Management LLC bought a new stake in BeOne Medicines during the second quarter worth approximately $26,000. Tower Research Capital LLC TRC acquired a new position in shares of BeOne Medicines during the 2nd quarter valued at $848,000. Two Sigma Securities LLC bought a new stake in shares of BeOne Medicines in the 2nd quarter worth $480,000. Snowden Capital Advisors LLC acquired a new stake in shares of BeOne Medicines in the second quarter valued at $223,000. Finally, Orion Porfolio Solutions LLC bought a new position in BeOne Medicines during the second quarter valued at about $524,000. Institutional investors own 48.55% of the company's stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.